Phase 2 N=5 PK/PD Comparison of Guanfacine ER and IR
Smoking
Primary: Plasma Trough Levels of Guanfacine — 3.40; 3.46; 5.92 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
Phase 2 N=522 Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse
Malaria, Vivax
Primary: Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose — 35; 155; 83 Participants — p=<0.001
Phase 2 N=15 Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
Leukemia
Primary: Overall Response (OR) — 3 Participants
Phase 4 N=1,405 Cornea Preservation Time Study
Cornea Preservation Time · Endothelial Keratoplasty · Transplant Success
Primary: Number of Eyes With Corneal Graft Failure Within 3 Years of Surgery — 30; 49 Eyes — p=0.02
N/A N=203 Alabama Veterans Rural Health Initiative
Problems With Access to Health Care · Health Behavior
Primary: Attendance at a VA Appointment — 88; 59 participants — p=<.0001
Phase 2 N=16 CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)
Melanoma
Primary: Safety — 16 participants
Phase 3 N=660 Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Pain · Advanced Cancer
Primary: Percent Of Participants With Treatment-emergent Adverse Events — 82.9 percent of participants
Phase 3 N=406 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer
Pain · Advanced Cancer
Primary: Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment — 0.5; 0.5 units on a scale — p=0.9173
Phase 2 N=42 A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
Lymphocytic Leukemia, Chronic
Primary: Overall Response Rate — 67.5 percentage of participants
Phase 4 N=54 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults
Weight Gain
Primary: Change in Weight From Baseline to Endpoint. — -1.1; 5.9 Pounds
Phase 3 N=68 A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Percentage of Participants With Clinically Significant Hypoglycemia — 6.6; 35.5 percentage of participants
N/A N=4 Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Phase 2 N=169 Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Intra-Ocular Pressure (IOP) at Week 2 — 24.99; 25.34; 23.65; 23.75 mm Hg
N/A N=24 Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Emphysema · Chronic Obstructive Pulmonary Disease (COPD) · Cystic Fibrosis
Primary: 30 Day Mortality and Graft Survival — 0; 22; 0; 2 Participants